Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial

Abstract Background In critically ill patients with severe infections, beta-lactam antibiotics are frequently underdosed, while studies indicate that shorter treatment durations may be sufficient when adequately dosed. The HIT-HARD trial aims to evaluate whether short-course, high-dose beta-lactam therapy is non-inferior to conventional dosing and duration in critically ill patients with severe infections. A shorter course may reduce the development of antimicrobial resistance and serve a public health benefit. Methods The HIT-HARD trial (EU ref. 2024-514730-21-00) is a prospective, multicenter, cluster-randomized, cross-over, non-inferiority trial conducted in 14 hospitals (7 in Belgium and 7 in the Netherlands). The study aims to enroll 1,282 patients with organ dysfunction due to common infections (community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, intra-abdominal infection, or bloodstream infection). Patients treated with ceftriaxone, cefuroxime, cefotaxime, piperacillin–tazobactam, or meropenem can be included in the study. Exclusion criteria include prior study-antimicrobial therapy > 12 h for the current infection, absence of adequate source control, and infections requiring prolonged or specific dosing regimens. Participants are allocated to either the HIT-HARD strategy, a high-dose regimen (around 150–200% of standard dosing) for a short course of 3–5 days (72–120 h), or the CONTROL strategy, a conventional dosing regimen for 6–9 days (144–216 h). The primary endpoint is all-cause 90-day mortality. Secondary endpoints include mortality, recurrence of infection, antimicrobial resistance development, toxicity, antimicrobial exposure, clinical cure, resource utilization, health-related quality of life, and cost-effectiveness. Non-inferiority will be assessed using a pre-specified 7% margin by estimating the risk difference between the HIT-HARD and CONTROL groups with an unweighted cluster-level summary regression. Discussion By determining whether this short-course, high-dose approach is non-inferior to conventional regimens, the trial has the potential to directly inform antibiotic policy and guide an evidence-based approach to safely shorten antimicrobial therapy as part of an ICU stewardship program. Trial registration 20245147302100 (EUCT), prospective trial registration date 05DEC2024. Protocol version 3.0, protocol date 01JUN2026.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2026-11-12
DOI
https://doi.org/10.1186/s12879-026-14707-3
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial

Nynke G L Jager, Jan J. De Waele, Jeroen A. Schouten, Leanne J. Kosse et al.
BMC Infectious Diseases
Antibiotics Pharmacokinetics and Efficacy
article

Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial

Nynke G L Jager, Jan J. De Waele, Jeroen A. Schouten, Leanne J. Kosse, Steven Teerenstra, Liesbet De Bus, Wietske Kievit, Roger J. M. Brüggemann, Jaap ten Oever, Maya Hites, Nicolas De Schryver, Jerina Boelens, Isabel Spriet, Charlotte H. S. B. van den Berg, M. Demaria, D. Vermeiren, On behalf of the HIT-HARD investigators
article en

Abstract

Abstract Background In critically ill patients with severe infections, beta-lactam antibiotics are frequently underdosed, while studies indicate that shorter treatment durations may be sufficient when adequately dosed. The HIT-HARD trial aims to evaluate whether short-course, high-dose beta-lactam therapy is non-inferior to conventional dosing and duration in critically ill patients with severe infections. A shorter course may reduce the development of antimicrobial resistance and serve a public health benefit. Methods The HIT-HARD trial (EU ref. 2024-514730-21-00) is a prospective, multicenter, cluster-randomized, cross-over, non-inferiority trial conducted in 14 hospitals (7 in Belgium and 7 in the Netherlands). The study aims to enroll 1,282 patients with organ dysfunction due to common infections (community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, intra-abdominal infection, or bloodstream infection). Patients treated with ceftriaxone, cefuroxime, cefotaxime, piperacillin–tazobactam, or meropenem can be included in the study. Exclusion criteria include prior study-antimicrobial therapy > 12 h for the current infection, absence of adequate source control, and infections requiring prolonged or specific dosing regimens. Participants are allocated to either the HIT-HARD strategy, a high-dose regimen (around 150–200% of standard dosing) for a short course of 3–5 days (72–120 h), or the CONTROL strategy, a conventional dosing regimen for 6–9 days (144–216 h). The primary endpoint is all-cause 90-day mortality. Secondary endpoints include mortality, recurrence of infection, antimicrobial resistance development, toxicity, antimicrobial exposure, clinical cure, resource utilization, health-related quality of life, and cost-effectiveness. Non-inferiority will be assessed using a pre-specified 7% margin by estimating the risk difference between the HIT-HARD and CONTROL groups with an unweighted cluster-level summary regression. Discussion By determining whether this short-course, high-dose approach is non-inferior to conventional regimens, the trial has the potential to directly inform antibiotic policy and guide an evidence-based approach to safely shorten antimicrobial therapy as part of an ICU stewardship program. Trial registration 20245147302100 (EUCT), prospective trial registration date 05DEC2024. Protocol version 3.0, protocol date 01JUN2026.

BMC Infectious Diseases
Université Libre de Bruxelles (BE), University Medical Center Groningen (NL), Radboud University Nijmegen (NL), University of Groningen (NL), Ghent University Hospital (BE), Radboud University Medical Center (NL), Ghent University (BE), Clinique Saint Pierre (BE), Radboud Institute for Health Sciences (NL), KU Leuven (BE)
ZonMw, Belgian Health Care Knowledge Centre
Good health and well-being
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon